Harmony Biosciences CEO Jeffrey Dayno (L) and CFO Sandip Kapadia
August 14, 2023 02:53 PM EDT
Deals
Pharma

Har­mo­ny looks to buy rare dis­ease drug de­vel­op­er in deal worth up to $200M

Paul Schloesser

Associate Editor

Har­mo­ny Bio­sciences is pay­ing $60 mil­lion in cash to get its hands on Zyner­ba Phar­ma­ceu­ti­cals and a ther­a­py it’s de­vel­op­ing to treat two rare dis­eases …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

Cal­tech spin­out de­buts with AI-dri­ven 'mir­ror pep­tide' plat­form

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times